SCHEMBL34510

SCHEMBL34510

O=[N+]([O-])c1ccc(NC2C(O)OC(CO)C(O)C2O)c2nonc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC5A2 P31639 1/20 0.51
GSTM2 P28161 1/20 0.49
GRK6 P43250 2/20 0.47
MEN1 O00255 7/20 0.46
KMT2A Q03164 7/20 0.46
POLB P06746 1/20 0.46
GAA P10253 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
USP2 O75604 1/20 0.46
HTT P42858 1/20 0.46
RECQL P46063 1/20 0.46
MYC P01106 4/20 0.46
IDO1 P14902 3/20 0.46
HK1 P19367 1/20 0.45
HK2 P52789 1/20 0.45
MAX P61244 1/20 0.44
MIF P14174 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14639838 1.00 SLC5A2 (0.51) SLC5A2GSTM2GRK6MEN1KMT2A
SCHEMBL15763297 1.00 SLC5A2 (0.51) SLC5A2GSTM2GRK6MEN1KMT2A
SCHEMBL15494585 1.00 SLC5A2 (0.51) SLC5A2GSTM2GRK6MEN1KMT2A
SCHEMBL29402554 1.00 SLC5A2 (0.51) SLC5A2GSTM2GRK6MEN1KMT2A
SCHEMBL15765529 1.00 SLC5A2 (0.51) SLC5A2GSTM2GRK6MEN1KMT2A
SCHEMBL14440339 1.00 SLC5A2 (0.51) SLC5A2GSTM2GRK6MEN1KMT2A
SCHEMBL12417486 1.00 SLC5A2 (0.51) SLC5A2GSTM2GRK6MEN1KMT2A
SCHEMBL12417485 1.00 SLC5A2 (0.51) SLC5A2GSTM2GRK6MEN1KMT2A
SCHEMBL15763307 1.00 SLC5A2 (0.51) SLC5A2GSTM2GRK6MEN1KMT2A
SCHEMBL15763313 1.00 SLC5A2 (0.51) SLC5A2GSTM2GRK6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2703495-B1 METHOD FOR DETECTING CANCER CELL USING FLUORESCENTLY LABELED L-GLUCOSE DERIVATIVE, AND CANCER CELL-IMAGING AGENT COMPRISING FLUORESCENTLY LABELED L-GLUCOSE DERIVATIVE UNIV HIROSAKI (JP) 2018-05-09 EP disclosed
US-8772463-B2 Fluorescent dye-labeled glucose bioprobe, synthesis method and usage thereof SNU R&DB FOUNDATION (KR) 2014-07-08 US disclosed
US-8772463-B2 Fluorescent dye-labeled glucose bioprobe, synthesis method and usage thereof SNU R&DB FOUNDATION (KR) 2014-07-08 US disclosed
US-8679854-B2 Fluorescent dye-labeled glucose bioprobe, synthesis method and usage thereof SNU & DB FOUNDATION (KR) 2014-03-25 US disclosed
US-8679854-B2 Fluorescent dye-labeled glucose bioprobe, synthesis method and usage thereof SNU & DB FOUNDATION (KR) 2014-03-25 US disclosed
US-8632749-B2 Two photon tracer, method for the preparation thereof and the use thereof in screening anticancer agents SNU R&DB FOUNDATION (KR) 2014-01-21 US disclosed
US-8632749-B2 Two photon tracer, method for the preparation thereof and the use thereof in screening anticancer agents SNU R&DB FOUNDATION (KR) 2014-01-21 US disclosed
US-20110059022-A1 TWO PHOTON TRACER, METHOD FOR THE PREPARATION THEREOF AND THE USE THEREOF IN SCREENING ANTICANCER AGENTS SNU R&DB FOUNDATION (KR) 2011-03-10 US disclosed
US-20110059022-A1 TWO PHOTON TRACER, METHOD FOR THE PREPARATION THEREOF AND THE USE THEREOF IN SCREENING ANTICANCER AGENTS SNU R&DB FOUNDATION (KR) 2011-03-10 US disclosed
US-20110059477-A1 FLUORESCENT DYE-LABELED GLUCOSE BIOPROBE, SYNTHESIS METHOD AND USAGE THEREOF SNU R&DB FOUNDATION (KR) 2011-03-10 US disclosed
US-20110059477-A1 FLUORESCENT DYE-LABELED GLUCOSE BIOPROBE, SYNTHESIS METHOD AND USAGE THEREOF SNU R&DB FOUNDATION (KR) 2011-03-10 US disclosed
US-20100105149-A1 FLUORESCENT DYE-LABELED GLUCOSE BIOPROBE, SYNTHESIS METHOD AND USAGE THEREOF SNU R&DB FOUNDATION (KR) 2010-04-29 US disclosed
US-20100105149-A1 FLUORESCENT DYE-LABELED GLUCOSE BIOPROBE, SYNTHESIS METHOD AND USAGE THEREOF SNU R&DB FOUNDATION (KR) 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059477-A1 FLUORESCENT DYE-LABELED GLUCOSE BIOPROBE, SYNTHESIS METHOD AND USAGE THEREOF OGA, UGGT1, GALE SLC5A2 20/4885GSTM2 1497/4885GRK6 1055/4885
US-20100105149-A1 FLUORESCENT DYE-LABELED GLUCOSE BIOPROBE, SYNTHESIS METHOD AND USAGE THEREOF GALE, OGA, GNE SLC5A2 10/4885GSTM2 2141/4885GRK6 1478/4885
US-20110059022-A1 TWO PHOTON TRACER, METHOD FOR THE PREPARATION THEREOF AND THE USE THEREOF IN SCREENING ANTICANCER AGENTS SLC2A2, SLC2A1, SLC2A9 SLC5A2 27/4885GSTM2 3152/4885GRK6 3447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.